MindMaze expands global reach of digital neurotherapeutics portfolio

MindMaze Healthcare, a global pioneer in the multibillion-dollar digital neurotherapeutics market, today announced four new partnership agreements that bring MindMaze’s digital neurotherapeutics to patients in Latin America, Middle East, Spain and Switzerland through agreements with Surgicorp, Alkholi, Guttmann Barcelona and Swiss Rehabilitation. With these agreements, MindMaze further expands its novel, protocolized, evidence-based interventions that are the future of brain repair worldwide.

MindMaze Healthcare is at the forefront of enhancing patient outcomes through its innovative digital neurotherapeutics (DTx) solutions that combine cutting-edge neuroscience with highly engaging, serious game-based medical software supported by tailored smart peripherals that target two distinct areas: neurorehabilitation (Rehab DTx) and neuro-restoration (Neuro DTx).

“MindMaze’s evidence-based interventions are leading an international paradigm shift in delivering novel, evidence-based therapies to patients for improved outcomes,” noted John Krakauer, M.A., M.D., Professor of Neurology at Johns Hopkins University School of Medicine, Director of the Center for the Study of Motor Learning and Brain Repair, and Chief Medical Advisor to MindMaze. “Importantly, MindMaze digital neurotherapeutic products are used across the continuum of care, from the hospital to home, offering patients a hybrid therapy program delivered through sessions in person and remotely that result in reduced therapy delivery costs and greater patient management and monitoring.”

The Company’s animated therapeutic ‘games’ aid patients suffering with neurological injuries and conditions such as stroke, traumatic brain injury, multiple sclerosis, or Parkinson’s disease. They were created to be as highly engaging as video games while promoting the high dose, high intensity therapeutic movements that lead to restoration of function.

“MindMaze products have proved to be the best in the market, as validated by the leading US institutions in the field. Thanks to distributors and partners, we can reach more patients faster, so that people with neurological diseases all around the world can benefit first-hand from these proven engaging and immersive therapies, including from the comfort of their own home,” said Jean-Marc Wismer, MindMaze’s Chief Operating Officer. “The partnerships collectively expand MindMaze’s international footprint, which should further solidify our leadership in brain health while contributing to our top line growth over the coming year and beyond.” NS Medical Devices